Uses protein imaging and machine learning to design influenza and RSV antiviral drugs, then runs them through clinical trials.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- ScaleMarket cap is in the bottom 5% globally
Uses protein imaging and machine learning to design influenza and RSV antiviral drugs, then runs them through clinical trials.
What this company is and how it runs — written from structure, not news.
Poolbeg Pharma uses crystallography images of viral proteins to train machine learning models that predict which small molecules will disrupt influenza or RSV replication, selecting drug candidates before any physical synthesis begins. Because every candidate that enters clinical trials is chosen by that same predictive filter, a systematic error in the model — say, misresolved protein structures or overfitting to a narrow set of viral strains — would invalidate the entire pipeline at once, since no independent discovery path exists to produce a clean alternative. The candidates that survive that filter then face a second constraint the company cannot buy its way around: RSV and influenza patients are only acutely infected during seasonal outbreak peaks, so missing a single enrollment window delays a whole trial phase by a full year, not a quarter. The computational side of the business can be extended to new viral targets relatively cheaply, but the clinical side runs on the virus's calendar and the regulator's documentation requirements, so the discovery engine will always move faster than the trial pipeline behind it.
How does this company make money?
Once a drug is approved, the company sells it per unit to hospitals and specialty pharmacies. In European markets, the price it can charge is set by health technology assessment agencies and negotiated with insurers — the company does not set the price freely. Revenue therefore depends on how many units are sold each season and on the reimbursement rates those agencies approve.
What makes this company hard to replace?
Regulatory agencies require that clinical trial data and manufacturing specifications remain consistent throughout a programme, so a competitor cannot simply take over a half-finished antiviral development programme — they would have to restart under their own data and approvals. Hospital formulary committees, which decide which drugs can be prescribed inside a hospital, require detailed safety evidence specific to each viral disease before they will add a new antiviral to their approved list, creating a separate documentation hurdle for any new entrant.
What limits this company?
Influenza and RSV patients are only available during seasonal outbreaks, so each trial phase has one recruitment window per year. If that window is missed — for any reason — the delay is a full year, not weeks. No amount of extra money can change this, because the outbreak calendar is set by the virus, not by the company.
What does this company depend on?
The company cannot operate without five things: the EMA's orphan drug designation for RSV, which defines the patient population and shapes trial design; contract research organisations that run the clinical trials; specialist CDMOs that manufacture the drug compounds under pharmaceutical-grade conditions; computational chemistry platforms used in drug design; and seasonal outbreaks of RSV and influenza that make acutely infected patients available to enroll.
Who depends on this company?
Hospital infectious disease units treating children with severe RSV currently have no targeted antiviral treatment and rely on supportive care — fluids, oxygen, monitoring — rather than a drug that attacks the virus directly. If this company stopped, those units would stay in that position. Pharmaceutical distributors that supply acute-care hospitals with seasonal infectious disease drugs would also lose access to any novel antivirals this company might bring to market.
How does this company scale?
The computational side — applying the crystallography and machine learning models to new viral targets — can expand to cover additional pathogens without a proportional rise in cost. The clinical side cannot be scaled in the same way. Regulatory agencies require fixed trial durations and mandatory safety monitoring periods, and those cannot be shortened regardless of how much money is available. So the discovery engine can grow faster than the trial engine ever can.
What external forces can significantly affect this company?
In European markets, health technology assessment agencies set reimbursement prices for new drugs regardless of what it cost to develop them, which squeezes the revenue the company can earn per unit sold. Climate change is shifting when and how severely RSV and influenza circulate each year, which could make the seasonal enrollment windows that trials depend on less predictable. Post-pandemic, regulators are also requiring more detailed safety documentation for any new infectious disease drug, adding time and cost to the approval process.
Where is this company structurally vulnerable?
If the viral protein structures used to train the machine learning model turn out to be measured incorrectly — or if the model has learned patterns that only work for a narrow set of viral strains — then every drug candidate the platform has selected shares the same flaw. Because all candidates pass through the same filter, a systematic error in that filter does not just sink one drug; it invalidates the entire pipeline at once.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
CompanyGraph